Lyell Immunopharma Inc (LYEL)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| CEO: | Elizabeth Homans |
| Employees: | 270 |
| Web site: | lyell.com |
|
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
650 695-0677
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Lyell Immunopharma, Inc. engages in developing T cell therapies for patients with solid tumors. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers. The company entered into research and development collaboration with GlaxoSmithKline for NY-ESO-1 program.